Patients not receiving biologic therapy (biologic-naïve: 5.89 ± 5.55) and those treated with TNF-α inhibitors (5.06 ± 4.39) had lower angioma counts than those on IL-23 inhibitors (6.94 ± 7.00). This evidence concerns the gene IL37 and hemangioma.